BioSpace News Archive

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a CE Mark from DEKRA Certification B.V. and Therapeutic Goods Administration (TGA) clearance in Australia to market NeoGraft 2.0 for hair restoration.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted four new employees non-qualified stock options to purchase an aggregate of 52,500 shares of Calithera’s common stock,

The majority of patients received riluzole alone, 4.2% were receiving edaravone alone, and 20.6% were receiving both.

Survey Results Highlight Continuing Strength of US Sector Along with Advances by Emerging Market Competitors

Technavio has announced its latest market research report titled global kidney stones management devices market 2019-2023

The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Albertsons Companies, one of the largest food and drug retailers in the United States, have partnered to provide HEPLISAV-B at Albertsons Companies’ more than 1,700 pharmacies nationwide, with a special focus on people living with diabetes.

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of leaders in the fields of de novo protein design, structural biology and immunology.

Transplant Genomics, Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics, today received notice that the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA has set TruGraf reimbursement at $2,840.75, per test performed.

Company’s innovative new product will aid in the early screening and detection of cancer